Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-a...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/18/4221 |
| _version_ | 1797518744195432448 |
|---|---|
| author | Yosuke Dotsu Hiroyuki Yamaguchi Minoru Fukuda Takayuki Suyama Noritaka Honda Yasuhiro Umeyama Hirokazu Taniguchi Hiroshi Gyotoku Shinnosuke Takemoto Ryuta Tagawa Ryosuke Ogata Hiromi Tomono Midori Shimada Hiroaki Senju Katsumi Nakatomi Seiji Nagashima Hiroshi Soda Hiroaki Ikeda Kazuto Ashizawa Hiroshi Mukae |
| author_facet | Yosuke Dotsu Hiroyuki Yamaguchi Minoru Fukuda Takayuki Suyama Noritaka Honda Yasuhiro Umeyama Hirokazu Taniguchi Hiroshi Gyotoku Shinnosuke Takemoto Ryuta Tagawa Ryosuke Ogata Hiromi Tomono Midori Shimada Hiroaki Senju Katsumi Nakatomi Seiji Nagashima Hiroshi Soda Hiroaki Ikeda Kazuto Ashizawa Hiroshi Mukae |
| author_sort | Yosuke Dotsu |
| collection | DOAJ |
| description | Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-agent amrubicin chemotherapy for thoracic malignancies. Patients and methods: The medical records of consecutive patients with thoracic malignancies, including SCLC and non-small cell lung cancer (NSCLC), who were treated with single-agent amrubicin chemotherapy in cycle 1 between January 2010 and March 2020, were retrospectively analyzed. Results: One hundred and fifty-six patients from four institutions were enrolled. Their characteristics were as follows: median age (range): 68 (32–86); male/female: 126/30; performance status (0/1/2): 9/108/39; SCLC/NSCLC/others: 111/30/15; and prior treatment (0/1/2/3-): 1/96/31/28. One hundred and thirty-four (86%) and 97 (62%) patients experienced grade 3/4 and grade 4 neutropenia, respectively. One hundred and twelve patients (72%) required therapeutic G-CSF treatment, and 47 (30%) developed FN. Prophylactic PEG-G-CSF was not used in cycle 1 in any case. The median overall survival of the patients with FN was significantly shorter than that of the patients without FN (7.2 vs. 10.0 months, <i>p</i> = 0.025). Conclusions: The real-world incidence rate of FN among patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy was 30%. It is suggested that prophylactic G-CSF should be administered during the practical use of single-agent amrubicin chemotherapy for patients who have already received chemotherapy. |
| first_indexed | 2024-03-10T07:32:56Z |
| format | Article |
| id | doaj.art-7cd27939594f433f940188255b3d3cd7 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T07:32:56Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-7cd27939594f433f940188255b3d3cd72023-11-22T13:41:31ZengMDPI AGJournal of Clinical Medicine2077-03832021-09-011018422110.3390/jcm10184221Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating FactorYosuke Dotsu0Hiroyuki Yamaguchi1Minoru Fukuda2Takayuki Suyama3Noritaka Honda4Yasuhiro Umeyama5Hirokazu Taniguchi6Hiroshi Gyotoku7Shinnosuke Takemoto8Ryuta Tagawa9Ryosuke Ogata10Hiromi Tomono11Midori Shimada12Hiroaki Senju13Katsumi Nakatomi14Seiji Nagashima15Hiroshi Soda16Hiroaki Ikeda17Kazuto Ashizawa18Hiroshi Mukae19Department of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, JapanDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, JapanDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, JapanDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, JapanDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, JapanDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, JapanMolecular Pharmacology Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, JapanDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, JapanDepartment of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Ohmura 856-8562, JapanDepartment of Respiratory Medicine, Sasebo City General Hospital, Sasebo 857-8511, JapanDepartment of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Ohmura 856-8562, JapanDepartment of Respiratory Medicine, Sasebo City General Hospital, Sasebo 857-8511, JapanDepartment of Respiratory Medicine, Sasebo City General Hospital, Sasebo 857-8511, JapanDepartment of Respiratory Medicine, National Hospital Organization Ureshino Medical Center, Ureshino 843-0393, JapanDepartment of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Ohmura 856-8562, JapanDepartment of Respiratory Medicine, Sasebo City General Hospital, Sasebo 857-8511, JapanDepartment of Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, JapanClinical Oncology Center, Nagasaki University Hospital, Nagasaki 852-8501, JapanDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, JapanBackground: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-agent amrubicin chemotherapy for thoracic malignancies. Patients and methods: The medical records of consecutive patients with thoracic malignancies, including SCLC and non-small cell lung cancer (NSCLC), who were treated with single-agent amrubicin chemotherapy in cycle 1 between January 2010 and March 2020, were retrospectively analyzed. Results: One hundred and fifty-six patients from four institutions were enrolled. Their characteristics were as follows: median age (range): 68 (32–86); male/female: 126/30; performance status (0/1/2): 9/108/39; SCLC/NSCLC/others: 111/30/15; and prior treatment (0/1/2/3-): 1/96/31/28. One hundred and thirty-four (86%) and 97 (62%) patients experienced grade 3/4 and grade 4 neutropenia, respectively. One hundred and twelve patients (72%) required therapeutic G-CSF treatment, and 47 (30%) developed FN. Prophylactic PEG-G-CSF was not used in cycle 1 in any case. The median overall survival of the patients with FN was significantly shorter than that of the patients without FN (7.2 vs. 10.0 months, <i>p</i> = 0.025). Conclusions: The real-world incidence rate of FN among patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy was 30%. It is suggested that prophylactic G-CSF should be administered during the practical use of single-agent amrubicin chemotherapy for patients who have already received chemotherapy.https://www.mdpi.com/2077-0383/10/18/4221amrubicinchemotherapygranulocyte colony-stimulating factorfebrile neutropenialung cancer |
| spellingShingle | Yosuke Dotsu Hiroyuki Yamaguchi Minoru Fukuda Takayuki Suyama Noritaka Honda Yasuhiro Umeyama Hirokazu Taniguchi Hiroshi Gyotoku Shinnosuke Takemoto Ryuta Tagawa Ryosuke Ogata Hiromi Tomono Midori Shimada Hiroaki Senju Katsumi Nakatomi Seiji Nagashima Hiroshi Soda Hiroaki Ikeda Kazuto Ashizawa Hiroshi Mukae Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor Journal of Clinical Medicine amrubicin chemotherapy granulocyte colony-stimulating factor febrile neutropenia lung cancer |
| title | Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor |
| title_full | Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor |
| title_fullStr | Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor |
| title_full_unstemmed | Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor |
| title_short | Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor |
| title_sort | real world incidence of febrile neutropenia among patients treated with single agent amrubicin necessity of the primary prophylactic administration of granulocyte colony stimulating factor |
| topic | amrubicin chemotherapy granulocyte colony-stimulating factor febrile neutropenia lung cancer |
| url | https://www.mdpi.com/2077-0383/10/18/4221 |
| work_keys_str_mv | AT yosukedotsu realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT hiroyukiyamaguchi realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT minorufukuda realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT takayukisuyama realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT noritakahonda realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT yasuhiroumeyama realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT hirokazutaniguchi realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT hiroshigyotoku realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT shinnosuketakemoto realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT ryutatagawa realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT ryosukeogata realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT hiromitomono realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT midorishimada realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT hiroakisenju realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT katsuminakatomi realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT seijinagashima realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT hiroshisoda realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT hiroakiikeda realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT kazutoashizawa realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor AT hiroshimukae realworldincidenceoffebrileneutropeniaamongpatientstreatedwithsingleagentamrubicinnecessityoftheprimaryprophylacticadministrationofgranulocytecolonystimulatingfactor |